VTAK Catheter Precision, Inc.

BULLISH Impact: 6/10 PRESS-RELEASE
Horizon months Filed Apr 21, 2026 Processed 1mo ago Wire GlobeNewswire
Press release: announcement
Latest settled — T+20d ⚠ clustered
VTAK ▼ -12.63% at T+20d
LONG call ✗ call lost -12.63% · α vs SPY -17.55% · entry $0.9500 → $0.8300
Next anchor: T+60d in 4w
Last close $1.05 (close Jun 12) · +10.53% from $0.9500 entry
Entry anchored
Apr 20, 03:58 PM ET
via Databento tick
T+1d
+1.05%
call +1.05% · α +0.03%
$0.9600
settled 8w ago
T+5d
-2.11%
call -2.11% · α -3.19%
$0.9300
settled 7w ago
T+20d
-12.63%
call -12.63% · α -17.55%
$0.8300
settled 27d ago
T+60d
call — · α —
in 4w

Price Chart

Loading chart...

Executive Summary

Catheter Precision, Inc. (VTAK) announced a Notice of Allowance from the USPTO for key patents covering its surgical vessel closing pressure device, strengthening its intellectual property position and competitive moat in the medical device space.

Actionable Insight

The patent allowance reduces technology risk and could attract partnership or acquisition interest; monitor for follow-on IP developments or commercial updates. Given VTAK's small market cap ($3M), even modest strategic progress could have outsized stock impact.

Key Facts

  • USPTO issued a Notice of Allowance for key claims covering VTAK's proprietary vessel closing pressure device.
  • Patent protection covers both core device architecture and method of use, enhancing IP defensibility.
  • Technology enables precise control of suture tension and pressure application post-vascular procedures.
  • LockeT, a related Class 1 device, is FDA-registered and has CE Mark approval.
  • Management emphasizes long-term value creation and strategic opportunities from IP expansion.

Financial Impact

Non-dilutive value enhancement through strengthened IP; no immediate revenue impact but improves commercialization and licensing potential.

intellectual_property_valuecompetitive_positionstrategic_options

Risk Factors

  • Forward-looking statements are subject to risks and uncertainties.
  • No assurance that patent allowance will lead to commercial success or revenue generation.
  • Company remains early-stage with unproven market adoption.

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3277839
11 reports for VTAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VTAK — sortable, filterable
Type Now
Jun 8, 2026
6d ago
Press Release
NEUTRAL ★ 3/10
$0.9875 awaiting T+20awaiting T+20$1.05 (+6.33%)
Jun 8, 2026
6d ago
8-K
NEUTRAL ★ 4/10
$0.9875 awaiting T+20awaiting T+20$1.05 (+6.33%)
May 4, 2026
5w ago
Press Release
NEUTRAL ★ 2/10
$0.9400 $0.9200▼ −2.13%▼ −7.77%$1.05 (+11.70%)
Apr 21, 2026
7w ago
Press Release
BULLISH ★ 6/10
$0.9500 $0.8300▼ −12.63%▼ −17.55%$1.05 (+10.53%)
Apr 20, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$0.9800 $0.8300▼ −15.31%▼ −19.51%$1.05 (+7.14%)
Apr 8, 2026
9w ago
Press Release
NEUTRAL ★ 3/10
$0.8600 $0.9300▲ +8.14%▼ −0.41%$1.05 (+22.09%)
Apr 6, 2026
9w ago
Press Release
NEUTRAL ★ 4/10
$0.9500 $0.9400▼ −1.05%▼ −10.04%$1.05 (+10.53%)
Mar 31, 2026
10w ago
8-K
MIXED ★ 6/10
$0.9400 $0.9400· 0.00%▼ −9.72%$1.05 (+11.70%)
Mar 31, 2026
10w ago
Press Release
MIXED ★ 6/10
$1.01 $0.9201▼ −8.90%▼ −18.32%$1.05 (+3.96%)
Mar 23, 2026
11w ago
DEFA14A
BEARISH ★ 7/10
$1.20 $0.9600▲ +20.00%▲ +28.90%$1.05 (+12.50%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 3h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access